Sindhu Igala, M.D.
Endocrinology, Diabetes & Metabolism Physician in Prosper, Texas.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,871 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Sindhu Igala, M.D. filed 4,364 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in Prosper, Texas, prescribing 36% generic.
- 4K
- Part D claims, 2023
- 36%
- generic prescribing
- $1.1K
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Sindhu Igala, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023, across all CMS prescribers nationally
4,364 Top 8% higher than 92% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
Sindhu Igala, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Sindhu Igala, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Texas
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Texas providers
Endocrinology, Diabetes & Metabolism Physician ranks #95 among Texas's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the Texas provider total, by primary NUCC taxonomy. The highlighted bar is Endocrinology, Diabetes & Metabolism Physician; the long tail of smaller specialties is omitted for legibility.
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Endocrinology, Diabetes & Metabolism Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Sindhu Igala, M.D. appears in the CMS NPPES registry as an Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 2120 PRAIRIE DR STE 301, Prosper, TX, 75078, with a listed phone of (214) 216-1359. NPI 1265760771 was issued on 11/20/2009.
Medicare Part D records for calendar year 2023 show 4,364 prescription claims written by this provider, covering 544 Medicare beneficiaries and totaling roughly $3.0 million in drug spend, split 54% brand-name and 36% generic by claim count.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,871 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1265760771 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 11/20/2009 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Sindhu Igala, M.D.'s current license status, disciplinary history, and board certifications with the Texas Medical Board in Texas before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1265760771 is the unique 10-digit identifier CMS uses to link Igala across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Sindhu Igala, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$1.1K
Largest payer
Abbott Laboratories
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Texas TMB 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 - they are NOT specific to Sindhu Igala, M.D.. To verify Sindhu Igala, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
54% brand-name claims vs 36% generic, on 4,364 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 9,837
- Total Day Supply
- 291,767
- Brand vs Generic
- 54% brand / 36% generic
- Brand Drug Cost
- $2.8M
- Generic Drug Cost
- $49K
Patient Demographics
- Average Patient Age
- 70.4 years
- Avg HCC Risk Score
- 1.90
- Gender Split
- 69% female / 31% male
- Age Distribution
- <65: 94, 65-74: 279, 75-84: 139, 85+: 32
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Sindhu Igala, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
402 claims
- Ozempic
Ozempic
399 claims
- Metformin Hcl
Metformin Hcl
165 claims
- Trulicity 148
Trulicity
148 claims
- Methimazole 124
Methimazole
124 claims
- Atorvastatin Calcium 122
Atorvastatin Calcium
122 claims
- Novolog Flexpen 120
Novolog Flexpen
120 claims
- Glimepiride 107
Glimepiride
107 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 402 |
| Ozempic Semaglutide | 399 |
| Metformin Hcl | 165 |
| Trulicity Dulaglutide | 148 |
| Methimazole | 124 |
| Atorvastatin Calcium | 122 |
| Novolog Flexpen Insulin Aspart | 120 |
| Glimepiride | 107 |
| Tresiba Flextouch U-200 Insulin Degludec | 93 |
| Pioglitazone Hcl | 84 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How Sindhu Igala, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
Sindhu Igala, M.D.'s 4,364 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Texas
Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as Igala.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Texas medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Texas
Frequently Asked Questions
What is Sindhu Igala, M.D.'s specialty? ▼
How much does Sindhu Igala, M.D. prescribe under Medicare Part D? ▼
Where is Sindhu Igala, M.D. located? ▼
What is Sindhu Igala, M.D.'s NPI number? ▼
Does Sindhu Igala, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does Sindhu Igala, M.D. prescribe most often? ▼
Does Sindhu Igala, M.D. accept Medicare? ▼
How can I verify Sindhu Igala, M.D.'s credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.
Published by
PlainDoctor Editorial
Independent public-data reference that compiles, verifies, and contextualizes official datasets. We do not accept compensation from entities we cover, and every dataset cites its originating public source.